CMPI - Checkmate Pharmaceuticals - Stock Forecast

Coverage Performance Price Targets & Ratings Chart Insider Trading

CMPI is currently covered by 1 analysts with an average price target of $4.39. This is a potential upside of $4.39 (0%) from yesterday's end of day stock price of $0.

Checkmate Pharmaceuticals's activity chart (see below) currently has 0 price targets and 2 ratings on display. The stock rating distribution of CMPI is 50% BUY and 50% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 100% with an average time for these price targets to be met of 106.5 days.

Highest price target for CMPI is $10, Lowest price target is $3, average price target is $4.39.

Most recent stock forecast was given by KAVERI POHLMAN from BTIG on 20-Apr-2022. First documented stock forecast 06-Oct-2021.

Best performing analysts who are covering CMPI - Checkmate Pharmaceuticals:

Geoff Meacham Kaveri Pohlman

Currently out of the existing stock ratings of CMPI, 1 are a BUY (50%), 1 are a HOLD (50%).

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

9

1 years 11 months 8 days ago

1/1 (100%)

$5.78 (179.50%)

20

Buy

7

$-3.5 (-33.33%)

2 years 5 months 20 days ago

1/1 (100%)

$2.99 (74.56%)

193

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is CMPI (Checkmate Pharmaceuticals) average time for price targets to be met?

On average it took 106.5 days on average for the stock forecasts to be realized with a an average price target met ratio 100

Which analyst has the current highest performing score on CMPI (Checkmate Pharmaceuticals) with a proven track record?

GEOFF MEACHAM

Which analyst has the current lower performing score on CMPI (Checkmate Pharmaceuticals) with a proven track record?

KAVERI POHLMAN

Which analyst has the most public recommendations on CMPI (Checkmate Pharmaceuticals)?

Geoff Meacham works at BAML and has 9 price targets and 7 ratings on CMPI

Which analyst is the currently most bullish on CMPI (Checkmate Pharmaceuticals)?

Kaveri Pohlman with highest potential upside - $0

Which analyst is the currently most reserved on CMPI (Checkmate Pharmaceuticals)?

Geoff Meacham with lowest potential downside - -$3.5

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?